1079 - Casirivimab and Imdevimab (CAS + IMD) Antibody Combination for the Treatment of Immunocomprised Hospitalized Patients with COVID-19

Friday, October 21, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

Presenting Author(s)

Selin Somersan-Karakaya, PhD

Medical Director Clinical Sciences
Regeneron Pharmaceuticals, Inc.
Tarrytown, New York, United States

Eleftherios Mylonakis, MD, PhD

Professor of Medicine, Professor of Molecular Microbiology and Immunology
Brown University
Providence, Rhode Island, United States
EO

Ernesto Oviedo-Orta, MD, PhD, MBA

Regeneron Pharmaceuticals, Inc.
Tarrytown, New York, United States
MO

Meagan P. O’Brien, MD

Regeneron Pharmaceuticals, Inc.
Tarrytown, New York, United States
VM

Veronica Mas Casullo, MD

Regeneron Pharmaceuticals, Inc.
Tarrytown, New York, United States
JM

Jenni Mou, PhD

Regeneron Pharmaceuticals, Inc.
Tarrytown, New York, United States
JX

Jing Xiao, PhD

Regeneron Pharmaceuticals, Inc.
Tarrytown, New York, United States
RB

Rafia Bhore, PhD

Regeneron Pharmaceuticals, Inc.
Tarrytown, New York, United States
AM

Adnan Mahmood, MD

Regeneron Pharmaceuticals, Inc.
Tarrytown, New York, United States
AH

Andrea T. Hooper, PhD

Regeneron Pharmaceuticals, Inc.
Tarrytown, New York, United States
MH

Mohamed Hussein, PhD

Regeneron Pharmaceuticals, Inc.
Tarrytown, New York, United States
SA

Shazia Ali, PharmD

Formerly of Regeneron Pharmaceuticals, Inc.
Tarrytown, New York, United States
EF

Eduardo Forleo-Neto, MD

Regeneron Pharmaceuticals, Inc.
Tarrytown, New York, United States
GH

Gary A. Herman, MD

Regeneron Pharmaceuticals, Inc.
Tarrytown, New York, United States
BH

Boaz Hirshberg, MD, MBA

Regeneron Pharmaceuticals, Inc.
Tarrytown, New York, United States
DW

David M. Weinreich, MD

Regeneron Pharmaceuticals, Inc.
Tarrytown, New York, United States